Skip to content

A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy

A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy in Medical Practice

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01876693
Enrollment
95
Registered
2013-06-12
Start date
2013-05-31
Completion date
2015-06-30
Last updated
2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Squamous Cell of Head and Neck

Brief summary

The purpose of the study is to determine whether prophylactic gastrostomy leads to less treatment interruption and provide better quality of life in head and neck cancer patients receiving chemoradiotherapy.

Detailed description

Nutritional status is one of the essential factor to determine outcome of chemoradiotherapy in head and neck cancer patients. Almost all these patients develop mucositis during the treatment, which usually leads to treatment interruptions and affects the efficacy of the treatment. Prophylactic gastrostomy has been accepted for these patients with improvement of quality of life. However, there is no prospective study confirming superiority of such treatment. The investigators enrolled head and neck cancer patients who had the plan of chemoradiotherapy. The patients will be informed about both treatment arms and will decide the arm that they preferred. The treatment interruptions, body weight and nutritional status will be assessed every 2 weeks during treatment period.

Interventions

PROCEDUREprophylactic percutaneous gastrostomy

prophylactic percutaneous gastrostomy with nutrition counselling

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* pathologically confirmed of head and neck cancer * plan to have chemoradiotherapy session * Performance status of 0-2

Exclusion criteria

* contraindications for percutaneous gastrostomy, eg coagulopathy, obstructed tumor * Body mass index less than 16 kg/m2

Design outcomes

Primary

MeasureTime frame
treatment interruption due to toxicityduring period of chemoradiatherapy, an expected average of 6 weeks

Secondary

MeasureTime frame
quality of lifeduring period of chemoradiation, an expected avearage of 6 weeks

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026